Regulus Therapeutics Inc. (RGLS)
Jun 25, 2025 - RGLS was delisted (reason: acquired by Novartis)
8.16
+0.02 (0.25%)
Inactive · Last trade price on Jun 24, 2025
United States Steel Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
34
Market Cap
n/a
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 10.01M | 3.17M | 46.46% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRGLS News
- 5 weeks ago - Novartis completes acquisition of Regulus Therapeutics - GlobeNewsWire
- 5 weeks ago - Novartis announces expiration of Regulus Therapeutics tender offer - GlobeNewsWire
- 2 months ago - Novartis announces commencement of tender offer to acquire Regulus Therapeutics - GlobeNewsWire
- 3 months ago - Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates - PRNewsWire
- 3 months ago - REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS - Business Wire
- 3 months ago - Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher - Benzinga
- 3 months ago - Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million - Benzinga
- 3 months ago - Novartis to Acquire Regulus in $1.7 Billion Deal - WSJ